Effect of nintedanib on composite physiologic index (CPI) in idiopathic pulmonary fibrosis (IPF)
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/1393003.congress-2017.oa3403
Abstract: Background: In the Phase III INPULSIS ® trials, nintedanib 150 mg twice daily slowed disease progression in patients with IPF by significantly reducing the annual rate of decline in FVC. Patients with FVC ≥50% predicted,… read more here.
Keywords: week; cpi; effect; effect nintedanib ... See more keywords
Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
Sign Up to like & getrecommendations! Published in 2020 at "Respiratory Research"
DOI: 10.1186/s12931-020-1298-1
Abstract: Background In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibrosis (IPF) with nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing disease… read more here.
Keywords: health related; hrqol; inpulsis; related quality ... See more keywords